Related Experiment Video

Updated: Jul 19, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

[Paediatric specificity of antifungals use]

Marie-Dominique Tabone1, Nathalie Le Guyader, Guy Leverger

  • 1Service d'Hémato-Oncologie Pédiatrique, Hôpital Trousseau, Paris, France. marie-dominique.tabone@trs.aphp.fr

Therapie
|September 23, 2006
PubMed

Insights

Optimizing antifungal use in children requires considering their unique mycoses epidemiology and pharmacokinetics. Limited data and rare approvals necessitate careful strategy development for pediatric antifungal treatment.

Area of Science:

  • Pediatric Pharmacology
  • Mycology
  • Infectious Diseases

Context:

  • Antifungal drug use in children presents unique challenges due to varying pharmacokinetics and limited approved agents.
  • Epidemiology of fungal infections (mycoses) in pediatric populations differs from adults, impacting treatment specificity.
  • Adverse event profiles and drug interactions in children require careful consideration.

Purpose:

  • To highlight the specific considerations for antifungal use in pediatric patients.
  • To underscore the scarcity of pharmacokinetic data and approved antifungal agents for children.
  • To emphasize the need for tailored treatment strategies based on individual pediatric cases.

Summary:

  • Antifungal efficacy in children is influenced by local mycoses epidemiology and age-dependent pharmacokinetics.
  • Limited pharmacokinetic data and a scarcity of approved antifungal medications in France complicate pediatric treatment.
  • Differences in adverse event frequency and potential drug interactions necessitate cautious prescribing in children.

Impact:

  • Informing the development of evidence-based guidelines for pediatric antifungal therapy.
  • Guiding clinicians in selecting appropriate antifungal agents and dosages for children.
  • Promoting safer and more effective management of fungal infections in pediatric populations.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...